title: [Usage, effectiveness and safety of abiraterone in prostate cancer].
abstract: OBJECTIVE
  After the marketing of Abiraterone, an androgen synthesis inhibitor, the aim of the study was to analyze its use, response, and safety in the population of a tertiary care level hospital.
  
  
  METHODS
  A retrospective observational study was carried out including all patients that were started on Abiraterone within a 21-month period. Demographical, diagnostic, therapeutic, and clinical variables were gathered. The response was assessed through the decreased of PSA as compared to baseline values. To assess the safety, all treatment-related adverse events were recorded.
  
  
  RESULTS
  A total of 45 patients were included of which 88.89% could be assessed for the drug effectiveness. The median baseline PSA value was 457.31 (range 9032-2.81). PSA decrease was ≥ 50%, ≥ 90% and < 30% in 16 (40%), 3 (7.5%) y 20 (50%), respectively. The most common grade 1-2 adverse events were fatigue (35.6%), increased liver enzymes (28.9%), hipokalemia (13.3%) and fluid retention (11.1%).
  
  
  CONCLUSIONS
  Abiraterone was a well tolerated drug that has shown to be active in prostate cancer patients previously treated with taxans, so it has been postulated as an alternative in this pathology.
authors.affiliation: Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España.. josemanuel.caro@salud.madrid.org.
authors.forename: J M
authors.initials: JM
authors.lastname: Caro Teller
authors.affiliation: Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España..
authors.forename: S
authors.initials: S
authors.lastname: Cortijo Cascajares
authors.affiliation: Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España..
authors.forename: I
authors.initials: I
authors.lastname: Escribano Valenciano
authors.affiliation: Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España..
authors.forename: O
authors.initials: O
authors.lastname: Serrano Garrote
authors.affiliation: Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España..
authors.forename: J M
authors.initials: JM
authors.lastname: Ferrari Piquero
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000736:Androstenes / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies
chemical_list: D000726:Androgen Antagonists; D000736:Androstenes; D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen; C089740:abiraterone